Indeed, universal screening with APRI was as effective as other selection strategies (i.e., presence of NAFLD or elevated ALT), reducing the number of needed biopsies while keeping the sensitivity stable. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.